Table 3.
Results from univariable models to predict attrition at 1 year.
| Attrition |
|||
|---|---|---|---|
| Independent Variable | Total | AE-Related | Non-AE-Related |
| Treatment | p < .0001 | p = .05 | p < .001 |
| Placebo | 34.9 ± 2.4a | 6.2 ± 0.8a | 30.5 ± 2.5a |
| Orlistat | 28.6 ± 2.5b | 7.8 ± 1.0a | 22.9 ± 2.6b |
| Sibutramine | 28.3 ± 3.3bc | 8.1 ± 1.8ac | 22.9 ± 3.9b |
| Rimonabant | 35.1 ± 3.2ac | 11.0 ± 1.6bc | 25.3 ± 3.6ab |
| Lead-In Period | p = .05 | p = .69 | p = .002 |
| Yes | 29.1 ± 2.6a | 8.4 ± 0.9 | 22.0 + 2.1a |
| No | 39.9 ± 4.5b | 7.8 ± 1.4 | 36.2 ± 3.6b |
| Comorbidity as Inclusion Criterion | p = .06 | p = .61 | p = .05 |
| Yes | 26.9 ± 3.3 | 8.7 ± 1.1 | 20.7 ± 3.1a |
| No | 35.9 ± 3.1 | 7.9 ± 1.0 | 29.9 ± 3.0b |
| Study Location | p = .10 | p = .93 | p = .27 |
| North America | 38.8 ± 4.1 | 8.6 ± 1.4 | 31.1 ± 4.3 |
| Europe | 27.3 ± 3.2 | 7.9 ± 1.1 | 22.0 ± 3.5 |
| Other | 32.6 ± 4.8 | 8.3 ± 1.5 | 24.7 ± 4.6 |
| Number of Study Visits | p = .19 | p = .97 | p = .11 |
| Number of Lifestyle Visits | p = .80 | p = .17 | p = .26 |
| Women in Study Group (%) | p = .02 | p = .32 | p = .01 |
| Mean Age of Study Group | p = .14 | p = .92 | p = .13 |
| Mean Body Mass Index of Study Group | p = .40 | p = .04 | p = .05 |
Note. The p values reported refer to the significance of each independent variable. For categorical variables, mean attrition rates (± standard errors) also are reported for each subgroup. Within each type of attrition, subgroup means marked with different subscripts were significantly different from each other at p < .05.